Bristol-Myers Squibb | BMY - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 6.57B 2.82B 2026-06
Abbott USD 6.8B 1.72B 2026-03
ALKERMES USD 511.53M 159.98M 2026-06
Amgen USD 13.99B 1.95B 2026-06
AstraZeneca USD 4.89B 2.67B 2026-06
Biogen USD 1.28B 2.1B 2026-06
Bristol-Myers Squibb USD 8.72B 852M 2026-06
Coherus Biosciences USD 82.92M 32.32M 2026-06
Drreddys Laboratories INR 15.37B 3.29B 2026-03
Eli Lilly USD 8.95B 3.67B 2026-06
Gilead Sciences USD 7.63B 64M 2026-03
GlaxoSmithKline GBP 3.44B 292M 2026-03
J&J USD 20.42B 1.27B 2026-06
Medtronic USD 1.95B 802M 2026-03
Merck USD 6.85B 1.52B 2026-06
Novartis USD 7.62B 739M 2026-06
Novo Nordisk A/S DKK 18.44B 5.78B 2025-06
Perrigo USD 357.2M 174.4M 2026-03
Pfizer USD 976M 727M 2026-06
Phibro Animal Health USD 61.42M 6.49M 2026-06
Prestige Brands USD 89.13M 25.26M 2026-06
Regeneron Pharmaceuticals USD 2.46B 506.8M 2026-06
Roche Holding CHF 7.55B 579M 2025-06
Sanofi EUR 6.35B 806M 2026-06
Sanofi EUR 5.54B 2.11B 2026-03
United Therapeutics USD 1.8B 523.5M 2026-06
Zoetis USD 1.48B 465M 2026-06